Figure S6. Correlation of number of potential binding neoepitopes with number of expressed (FPKM≥2) neoepitopes. The number of potential binding neoepitopes (IEDB score ≤ 500) are highly correlated with the number of expressed neoepitopes (FPKM≥2) for all three subtypes of breast cancer. In all the plots a linear regression model is used to fit the data; the fitted line is shown in red and 95% CIs are shown in grey (PDF 255 kb
Table S2. Patient and tumor characteristics. Demographic data for patients and clinical measurements...
Figure S9. Kaplan-Meier estimates for high and low mutation burden. KM survival curves are shown for...
The correlation diagrams of CD8 + TIL, FOXP3 + TIL, and CD8/FOXP3 ratio with residual cancer burden ...
Figure S3. Correlation of number of potential binding neoepitopes with number of nonsynonymous mutat...
Figure S7. Expression analysis for the high affinity neoepitopes (FPKM ≥2). (A) The number of the ex...
Figure S5. Expressed neoepitopes (FPKM≥5) in subtypes of breast cancer. The range of expressed neoep...
Figure S4. Length of potential binding neoepitopes in breast cancer. The number of potential binding...
Figure S10. Kaplan-Meier estimates by neoepitope load. KM curves of (A) disease-free survival and (B...
Figure S11. Kaplan-Meier estimates based on mutation burden and neoepitope load. KS curves of (A) di...
Figure S8. Distribution of neoepitopes binding to HLA class I alleles in the three subtypes of breas...
Table S3. Number of neoepitopes predicted for HLA class I alleles in all the breast cancer samples a...
Table S1. Number of patients for breast cancer subtype in the TCGA dataset according to IHC status. ...
Supplementary Information. Contains Supplementary Figures S1-S8 and Supplementary Tables S1-S4, S6-S...
Figure S1. Frequently mutated genes in TCGA breast cancer data. Here we show the mo for: (A) ER/PR(+...
Figure S2. Comparison of mutations called by the current protocol versus cBioportal ( http://www.cbi...
Table S2. Patient and tumor characteristics. Demographic data for patients and clinical measurements...
Figure S9. Kaplan-Meier estimates for high and low mutation burden. KM survival curves are shown for...
The correlation diagrams of CD8 + TIL, FOXP3 + TIL, and CD8/FOXP3 ratio with residual cancer burden ...
Figure S3. Correlation of number of potential binding neoepitopes with number of nonsynonymous mutat...
Figure S7. Expression analysis for the high affinity neoepitopes (FPKM ≥2). (A) The number of the ex...
Figure S5. Expressed neoepitopes (FPKM≥5) in subtypes of breast cancer. The range of expressed neoep...
Figure S4. Length of potential binding neoepitopes in breast cancer. The number of potential binding...
Figure S10. Kaplan-Meier estimates by neoepitope load. KM curves of (A) disease-free survival and (B...
Figure S11. Kaplan-Meier estimates based on mutation burden and neoepitope load. KS curves of (A) di...
Figure S8. Distribution of neoepitopes binding to HLA class I alleles in the three subtypes of breas...
Table S3. Number of neoepitopes predicted for HLA class I alleles in all the breast cancer samples a...
Table S1. Number of patients for breast cancer subtype in the TCGA dataset according to IHC status. ...
Supplementary Information. Contains Supplementary Figures S1-S8 and Supplementary Tables S1-S4, S6-S...
Figure S1. Frequently mutated genes in TCGA breast cancer data. Here we show the mo for: (A) ER/PR(+...
Figure S2. Comparison of mutations called by the current protocol versus cBioportal ( http://www.cbi...
Table S2. Patient and tumor characteristics. Demographic data for patients and clinical measurements...
Figure S9. Kaplan-Meier estimates for high and low mutation burden. KM survival curves are shown for...
The correlation diagrams of CD8 + TIL, FOXP3 + TIL, and CD8/FOXP3 ratio with residual cancer burden ...